Michael Chisamore
About
Michael Chisamore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, Michael Chisamore has authored 116 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 29 papers in Immunology. Recurrent topics in Michael Chisamore's work include Cancer Immunotherapy and Biomarkers (68 papers), CAR-T cell therapy research (20 papers) and Immunotherapy and Immune Responses (19 papers). Michael Chisamore is often cited by papers focused on Cancer Immunotherapy and Biomarkers (68 papers), CAR-T cell therapy research (20 papers) and Immunotherapy and Immune Responses (19 papers). Michael Chisamore collaborates with scholars based in United States, Spain and Italy. Michael Chisamore's co-authors include Hilary Wilkinson, Osvaldo Flores, V. Craig Jordan, Debra A. Tonetti, Yanyun Chen, David J. Bentrem, Hope S. Rugo, Sara M. Tolaney, Peter Kabos and John R. Lurain and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Michael Chisamore
106 papers receiving 1.0k citations
Peers
Michael Chisamore
Andrea E. Wahner Hendrickson United States
Mónica Musteanu Spain
Parham Minoo Canada
Joseph P. Garay United States
Yiqun Zhang United States
Ombretta Melaiu Italy
Cenap Güngör Germany
Christopher Ruel United States
Roberto A. Leon‐Ferre United States
François Ringeisen France
Citations per year, relative to Michael Chisamore Michael Chisamore (= 1×)
peers
Andrea E. Wahner Hendrickson
Countries citing papers authored by Michael Chisamore
Since
Specialization
Citations
This map shows the geographic impact of Michael Chisamore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Chisamore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Chisamore more than expected).
Fields of papers citing papers by Michael Chisamore
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael Chisamore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Chisamore. The network helps show where Michael Chisamore may publish in the future.
Co-authorship network of co-authors of Michael Chisamore
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Chisamore. A scholar is included among the top collaborators of Michael Chisamore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Chisamore. Michael Chisamore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Reck, Martin, Jyoti D. Patel, Jhanelle E. Gray, et al.. (2025). First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. Journal of Thoracic Oncology. 21(3). 103509–103509.
2.
Khattak, Muhammad A., P.A. Ascierto, Carolina Cimminiello, et al.. (2025). 1516MO EVX-01, a personalized cancer vaccine, induces potent T cell responses and durable disease control in advanced melanoma: 2-year follow-up. Annals of Oncology. 36. S845–S845.
3.
Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747.
4.
McKay, Rana R., Pedro C. Barata, Moshe Chaim Ornstein, et al.. (2024). 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605. The Oncologist. 29(Supplement_1). S13–S13.
5.
Gray, Janet, Joel W. Neal, Jyoti D. Patel, et al.. (2024). OA08.07 Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study. Journal of Thoracic Oncology. 19(10). S27–S27.
6.
Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538.
7.
Aerts, Joachim G.J.V., Luis Paz‐Ares, Carole Hélissey, et al.. (2024). Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 2533–2533.
8.
Burns, Timothy F., Konstantin H. Dragnev, Yutaka Fujiwara, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8510–8510.
9.
Fujiwara, Yutaka, Timothy F. Burns, Konstantin H. Dragnev, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(23_suppl). 195–195.
10.
Rohrberg, Kristoffer Staal, Zsuzsanna Pápai, Rikke Løvendahl Eefsen, et al.. (2024). 19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2641–2641.
11.
Ooki, Akira, Kei Muro, Kazumi Nishino, et al.. (2024). Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.. Journal of Clinical Oncology. 42(16_suppl). 4047–4047.
12.
Levy, Benjamin, Luis Paz‐Ares, Wu‐Chou Su, et al.. (2024). Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.. Journal of Clinical Oncology. 42(16_suppl). 8617–8617.
13.
Cavalcante, Ludimila, Sreenivasa R Chandana, Nehal J. Lakhani, et al.. (2024). Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for ImmunoTherapy of Cancer. 12(8). e009475–e009475.
14.
Cho, Byoung Chul, Rubén Cabanillas, David Vicente Baz, et al.. (2023). OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study. Journal of Thoracic Oncology. 18(11). S54–S54.
15.
Kim, Tae Min, Nuttapong Ngamphaiboon, Ki Hyeong Lee, et al.. (2023). 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor. SHILAP Revista de lepidopterología. A1808–A1808.
16.
Thomas, Stacy K., Max M. Wattenberg, Mark Uhlik, et al.. (2023). Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nature Communications. 14(1). 6330–6330.
17.
Schöffski, Patrick, Rastislav Bahleda, Andrew J. Wagner, et al.. (2023). Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 29(17). 3320–3328.
18.
Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113.
19.
Zhang, Yiyun, et al.. (2009). Estradiol-Induced Regression in T47D:A18/PKCα Tumors Requires the Estrogen Receptor and Interaction with the Extracellular Matrix. Molecular Cancer Research. 7(4). 498–510.
20.
Chisamore, Michael, et al.. (2009). Estrogen-related receptor-α antagonist inhibits both estrogen receptor–positive and estrogen receptor–negative breast tumor growth in mouse xenografts. Molecular Cancer Therapeutics. 8(3). 672–681.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Andrea E. Wahner Hendrickson Breakdown of academic impact, for papers by Mónica Musteanu Breakdown of academic impact, for papers by Parham Minoo Breakdown of academic impact, for papers by Joseph P. Garay Breakdown of academic impact, for papers by Yiqun Zhang Breakdown of academic impact, for papers by Ombretta Melaiu Breakdown of academic impact, for papers by Cenap Güngör Breakdown of academic impact, for papers by Christopher Ruel Breakdown of academic impact, for papers by Roberto A. Leon‐Ferre Breakdown of academic impact, for papers by François Ringeisen